Pharmabiz
 

Two-day intl conference on clinical trial in Mumbai from Nov 19

Our Bureau, MumbaiThursday, November 18, 2010, 15:30 Hrs  [IST]

Confederation of Indian Industry (CII) in alliance with Department of Science and Technology (DST), Quality Council of India (QCI), Ministry of Health and Family Welfare and Department of Pharmaceuticals is organizing an international conference introducing the new trends and opportunities on clinical trials on November 19-20, 2010 in Mumbai.

The objective of the conference is to showcase the development in the clinical trial practices by bringing together all stakeholders to a single platform, to create a platform for deliberation on creating conducive regulatory for clinical research to meet global standards and to showcase the competitiveness of Indian clinical research industry to the international stakeholders and also to facilitate meaningful interactions for possible joint ventures.

The conference is significant as India has been looked up as a favorable destination for conducting global clinical trials. It provides an opportunity in terms of availability of large patient pool, highly educated talent, wide spread of diseases, low cost of operations and a favorable economic and IRR environment. Though India has become one of the major destinations for clinical trial outsourcing, there is a need for robustness in the IRB and regulatory mechanism so that the clinical trial data generated in India is well accepted globally. One should notice the fact that clinical trial outsourcing is growing at tremendous rate and all global pharmaceutical R&D’s are moving towards Eastern Countries and India is the most sought destination. It is estimated that Indian CRO industry is expected to achieve 5 per cent of 36 billion dollars of US market.

The Conference is expected to be a platform for discussions and interactions with the top CRO’s across the country and the globe with the primary focus to preview the current status of Indian CRO’s as compared to the global market and regulatory requirements for making the Indian clinical trials data accepted globally. It will also showcase the strengths of Indian CRO’s and the opportunities that are lined up.

 
[Close]